VC-backed Cynapsus Therapeutics sees IPO raising up to $67 mln
Cynapsus Therapeutics Inc has set the terms of its previously announced initial public offering on the NASDAQ. The company plans to sell 4.5 million common shares and, potentially, a further 675,000 shares in an option granted to underwriters. At a recently quoted price per share of US$14.18, a filing with the U.S. Securities and Exchange Commission suggests the company expects to generate up to US$67.2 million. Based in Toronto, Cynapsus is a maker of drugs to treat patients suffering from Parkinson’s disease. It is backed by U.S. venture capital firms OrbiMed Advisors, Aisling Capital and Venrock.
11 June 2015•5 mins read
